Genprex

Monthly Archives: May 2024

Genprex to Present at the 2024 BIO International Convention

Presentation to Highlight the Company’s Gene Therapies for Cancer and Diabetes

Read More



Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors

Read More

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner

Ryan Confer Appointed Genprex President and CEO and to its Board of Directors

Read More

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences

AUSTIN, Texas — (May. 1, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company’s participation in the following upcoming investor and industry conferences to be held in May 2024.

Read More